Analysis of clinical distribution and drug resistance of low respiratory tract infection of Pseudomonas aeruginosa in elderly patients

Objective To study the clinical distribution and drug resistance in patients with lower respiratory tract infection caused by Pseudomonas aeruginosa. Method Elderly patients with lower respiratory tract infection were collected,156 sputum samples werr isolated and cultured from sputum specimens of Pseudomonas aeruginosa,156 strains of Pseudomonas aeruginosa isolated from clinical specimens by VITEK2-Compact automatic bacteria identification and drug sensitivity were analyed,and the drug sensitivity test in vitro was done by agar diffusion method,according to CLSI latest break point,the results were gotten. Results Non MDR clinical isolates of pseudomonas aeruginosa to cefotaxime,sulfamethoxazole / trimethoprim resistance was the highest,resistance rate was more than 70%; to imipenem,meropenem, aztreonam and cefoperazone / shubatan,ceftazidime,piperacillin / sulbactam,Amikacin resistance rates were within 20%,imipenem and meropenem sensitivity reached 100%. While the MDR strain to piperacillin,cefotaxime,ciprofloxacin,gentamicin,tobramycin,sulfamethoxazole / trimethoprim highly resistant,resistant rate was 100%,to piperacillin / tazobactam,cefepime,amikacin resistance up to 60%,to imipenem,meropenem,aztreonam was still good sensitivity,drug resistance was lower than 20%. Conclusion Imipenem and meropenem have better sensitivity of pseudomonas aeruginosa,the drug of choice in patients with severe lower respiratory tract infection with pseudomonas aeruginosa treatment,such as MDR of pseudomonas aeruginosa infection,can be combined with medication. We should strengthen the rational use of antibiotics in hospital and standardize clinical drug.